Effect of dichloromethylene diphosphonate (Cl2MDP) on immune function in breast cancer patients with bone metastases.
Immune function was studied in normocalcemic breast cancer patients with bone metastases treated with either dichloromethylene diphosphonate (Cl2MDP) or placebo. The results showed no significant difference between the two patient groups. This suggests that Cl2MDP does not markedly impair the host's defense mechanisms, and in this respect can be safely used in the treatment of patients with resorptive bone disease.
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000276:immunology / Q000556:secondary*; D001943:Breast Neoplasms / Q000276:immunology*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D004002:Clodronic Acid; D004164:Diphosphonates; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008875:Middle Aged; D010919:Placebos
D004164:Diphosphonates; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010919:Placebos; D004002:Clodronic Acid